Cardiovascular complications in COVID-19: A systematic review and meta-analysis

Kunutsor, Setor K; Laukkanen, Jari A.

doi:10.1016/j.jinf.2020.05.068

Cited by 65 publications

(68 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ventricular tachycardia/VF arrest and pulseless electrical activity were reported by 4.8% and 5.6% of respondents, respectively. A meta-analysis of 17 retrospective cohort studies comprising 5,815 patients with COVID-19 showed that the pooled incidence was 9.3% for cardiac arrhythmia (5.7% for cardiac arrest) [14] .…”

Section: Introductionmentioning

confidence: 99%

COVID-19 infection and cardiac arrhythmias

Manolis¹,

Manolis

et al. 2020

Trends in Cardiovascular Medicine

112

View full text Add to dashboard Cite

Highlights Serious cardiac arrhythmias may be the consequence of direct effects of COVID-19 infection, but also the outcome of the deleterious effects of systemic illness and the adverse proarrhythmic reactions to drugs employed in the treatment of this pandemic Drug combinations, especially of QT-prolonging agents, can lead to higher arrhythmogenicity, compared with single drug therapies Furthermore, critically ill COVID-19 patients often have comorbidities that can trigger life-threatening ventricular arrhythmias, while acute myocardial injury increases the prevalence of arrhythmias ECG and QTc monitoring and taking appropriate measures are of critical importance to prevent, detect and manage cardiac arrhythmias in COVID-19 patients Contactless monitoring and telemetry for inpatients, especially those admitted to the ICU, as well as for outpatients needing continued management, has recently been facilitated by implementing digital health monitoring tools

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 infection and cardiac arrhythmias

Manolis¹,

Manolis

et al. 2020

Trends in Cardiovascular Medicine

112

View full text Add to dashboard Cite

show abstract

“…The coronavirus disease 2019 (COVID-19) pandemic which is one of the most significant modern-day public health challenges, predominantly affects the respiratory system, causing severe pneumonia and respiratory distress syndrome. Emerging data suggests COVID-19 adversely affects multiple organs; gastrointestinal, liver, kidney, neurological and cardiac complications have been reported [ [2] , [3] , [4] ]. Apart from pre-existing comorbidities such as CVD, hypertension, chronic kidney disease, chronic liver disease and diabetes being linked to increased risk of severe illness or death; [ 5 ] some extrapulmonary complications of COVID-19 such as acute myocardial injury have been shown to be associated with fatal outcomes [ 6 ].…”

mentioning

confidence: 99%

“…Though arterial thrombosis and VTE have historically been viewed as two distinct diseases with different pathophysiology, they appear to be closely related via some shared risk factors (obesity and smoking) and mechanistic pathways (such as coagulation, platelet activation and dyslipidaemia) [ 1 ]. Though the mechanistic pathways are still not very clear, the predisposition to venous and arterial thromboembolism by COVID-19 especially in severe infection has been attributed to the overwhelming inflammatory response, hypoxia, DIC and immobilisation [ 2 ]. There is an on-going discussion that pulmonary thrombotic events in COVID-19 may not be due to emboli but rather as a result of in-situ pulmonary thrombosis [ 10 ].…”

mentioning

confidence: 99%

Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis

Kunutsor

Laukkanen

2020

Thrombosis Research

Self Cite

View full text Add to dashboard Cite

Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysisTo the Editors Arterial thrombotic disease (atherosclerotic cardiovascular disease, CVD) and venous thromboembolism (VTE) (comprising of deep vein thrombosis (DVT) and pulmonary embolism (PE)), two distinct but closely related diseases, [1] constitute major public health problems and are associated with substantial morbidity, premature mortality, and high economic costs. The coronavirus disease 2019 (COVID-19) pandemic which is one of the most significant modern-day public health challenges, predominantly affects the respiratory system, causing severe pneumonia and respiratory distress syndrome. Emerging data suggests COVID-19 adversely affects multiple organs; gastrointestinal, liver, kidney, neurological and cardiac complications have been reported [2][3][4]. Apart from pre-existing comorbidities such as CVD, hypertension, chronic kidney disease, chronic liver disease and diabetes being linked to increased risk of severe illness or death; [5] some extrapulmonary complications of COVID-19 such as acute myocardial injury have been shown to be associated with fatal outcomes [6]. Recently, COVID-19 has been linked to venous and arterial thromboembolic disease (henceforth referred to as thromboembolic complications). Three recent most downloaded and key studies published in the journal reported a high incidence of thromboembolic complications in COVID-19 patients, particularly in those admitted to the intensive care unit (ICU) [7][8][9]. Given the sparseness of the data and evolving nature of the disease, the thromboembolic complications of COVID-19 and their incidence estimates are not clearly defined. There is a need for robust aggregation of data on thromboembolic complications of COVID-19, which will be of great value for policy makers, healthcare providers and clinicians to aid decision making and implementing more efficacious preventative strategies. In this context, we conducted a systematic review and meta-analysis to attempt to address the following questions: (i) what are the thromboembolic complications associated with what is the incidence of these complications overall and in those who develop severe disease?The review was conducted in accordance with PRISMA and MOOSE guidelines (Supplementary Materials 1-2). We searched MEDLINE and Embase from January 2020 to 6 August 2020 for published studies reporting on venous and arterial thromboembolic complications (e.g., VTE, PE, myocardial infarction (MI), acute coronary syndrome (ACS), ischemic stroke, disseminated intravascular coagulation (DIC)) in patients with COVID-19. Studies based on selected patients/populations (eg, cancer patients) were not included. Details of the search strategy fection. A scoping review, Thromb. Res. 192 (2020) 152-160.

show abstract

“…While it appears that the present approaches to bibliographical indexing may not adequately meet the current data search needs, workable, timely solutions are not readily apparent. Temporizing approaches, such as consistent inclusion of the study type in manuscript titles, especially when reported in a letter form [13,14], may offer better data transparency, though this will not reduce the volume of potentially relevant retrieved citations. However, the practicality of even such limited-scope approaches remains to be determined.…”

Section: To the Editormentioning

confidence: 99%

Identifying the Quality Nuggets Amid the Explosion of COVID-19-Related Scientific Communication: An Insurmountable Challenge?

Oud

2020

J Clin Med Res

View full text Add to dashboard Cite

Cardiovascular complications in COVID-19: A systematic review and meta-analysis

Cited by 65 publications

References 11 publications

COVID-19 infection and cardiac arrhythmias

COVID-19 infection and cardiac arrhythmias

Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis

Identifying the Quality Nuggets Amid the Explosion of COVID-19-Related Scientific Communication: An Insurmountable Challenge?

Contact Info

Product

Resources

About